Mauna Kea Technologies (ALMKT.PA) Stock Price
Mauna Kea Technologies Price
Over the last 17 years Mauna Kea Technologies grew revenue by 3.9% annually, reaching 8.22 M EUR. For Mauna Kea Technologies, the net margin of 131.0% is up versus -174.6% a few years ago.
Mauna Kea Technologies stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Mauna Kea Technologies business model & stock analysis
Frequently asked questions about Mauna Kea Technologies
The business model of Mauna Kea Technologies SAS revolves around pioneering and delivering innovative endomicroscopy solutions. As a global medical device company, Mauna Kea specializes in developing and commercializing probe-based Confocal Laser Endomicroscopy (pCLE) technology. This enables real-time visualization of tissue at the cellular level during minimally invasive procedures. By combining advanced imaging capabilities with their Cellvizio platform, Mauna Kea enables medical professionals to improve patient care and treatment outcomes. Through strategic partnerships and commercialization efforts, the company aims to leverage its cutting-edge technologies to enhance diagnostic procedures and revolutionize healthcare practices worldwide.
Mauna Kea Technologies SAS is primarily active in the medical industry, specifically in the field of innovative medical devices.
The main competitors of Mauna Kea Technologies SAS in the market include companies such as Intuitive Surgical, Medtronic, Olympus Corporation, and Pentax Medical.
Mauna Kea Technologies SAS is a renowned medical technology company specializing in the development and commercialization of innovative optical biopsy products. Founded in 2000, the company has focused on revolutionizing the detection and treatment of cancer and other diseases through its proprietary Cellvizio® platform. Mauna Kea Technologies has successfully integrated high-resolution imaging and miniaturized endomicroscopy into its advanced devices, enabling physicians to perform real-time, in vivo microscopy during standard procedures. With a commitment to improving patient outcomes and advancing medical knowledge, Mauna Kea Technologies SAS continues to drive advancements in optical biopsy technology worldwide. Find out more about Mauna Kea Technologies SAS on our stock website.
Mauna Kea Technologies SAS has achieved several significant milestones throughout its history. The company introduced Cellvizio, a breakthrough endomicroscopy platform, which has transformed the way physicians diagnose and monitor diseases. The technology has gained widespread recognition and has been adopted by renowned medical institutions globally. Furthermore, Mauna Kea Technologies SAS secured regulatory approvals for its innovative products, strengthening its market position and expanding its customer base. The company's dedication to research and development has led to numerous patents and advancements in optical biopsy solutions. Overall, Mauna Kea Technologies SAS has consistently demonstrated its commitment to advancing medical imaging and improving patient care.
Mauna Kea Technologies SAS is primarily present in several countries and regions globally. It has a significant presence in the United States, particularly in the New York City metropolitan area. In addition, the company operates extensively in Europe, with a strong presence in France, Germany, Italy, Spain, and the United Kingdom. Mauna Kea Technologies SAS also has a growing market share in the Asia-Pacific region, including Australia, China, Japan, and South Korea. With its widespread international presence, Mauna Kea Technologies SAS continues to expand its reach and impact in the field of medical technology and innovative imaging solutions.
Mauna Kea Technologies SAS represents a set of core values and a corporate philosophy that is deeply rooted in innovation, excellence, and patient-centricity. The company strives to revolutionize medical imaging and diagnostics by developing cutting-edge medical devices and technology solutions. Mauna Kea Technologies SAS is committed to improving patient outcomes by providing physicians with real-time, high-resolution imaging capabilities for a more accurate and precise diagnosis. The company also prioritizes ethical practices, sustainable development, and collaboration with healthcare professionals to advance the field of medical imaging. Mauna Kea Technologies SAS is dedicated to pushing boundaries and constantly striving for excellence in the healthcare industry.
9 analysts currently rate the Mauna Kea Technologies stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Mauna Kea Technologies to generate revenue of 7.75 M EUR and earnings per share of -0.01 EUR.
The Mauna Kea Technologies share (ALMKT.PA) is listed on 6 stock exchanges, including: London (0P5I.L), Frankfurt (1MK.F), München (1MK.MU), Paris (MKEA.PA).
Mauna Kea Technologies SAS is a French company that specializes in the development and marketing of medical devices and procedures that provide precise diagnostic and therapeutic solutions for various types of cancer. The company uses its patented technologies to develop applications for endoscopic imaging, fluorescence microscopy, and optical biopsy.
The expected revenue of Mauna Kea Technologies is 7.75 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Mauna Kea Technologies is -1.75 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Mauna Kea Technologies is currently -8.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mauna Kea Technologies stock.
The price-to-sales ratio (P/S) of Mauna Kea Technologies is currently 2.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mauna Kea Technologies stock.
The Eulerpool Quality Score for Mauna Kea Technologies is 1/10.
The ISIN of Mauna Kea Technologies is FR0010609263. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Mauna Kea Technologies is A1JCLA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Mauna Kea Technologies is ALMKT.PA. The ticker symbol is used to trade Mauna Kea Technologies shares on the stock exchange.
Mauna Kea Technologies stock
Mauna Kea Technologies Peer Group
Mauna Kea Technologies Ticker
Mauna Kea Technologies FIGI
All fundamentals and in-depth analysis of Mauna Kea Technologies
Our stock analysis for Mauna Kea Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mauna Kea Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.